Early quantification of systemic inflammatory-proteins predicts long-term treatment response to Tofacitinib and Etanercept: Psoriasis response predictions using blood.

[1]  H. Valdez,et al.  Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. , 2017, The Journal of investigative dermatology.

[2]  J. Krueger,et al.  Psoriasis pathogenesis and the development of novel targeted immune therapies , 2017, The Journal of allergy and clinical immunology.

[3]  S. Tian,et al.  Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment. , 2017, The Journal of investigative dermatology.

[4]  J. Krueger,et al.  Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. , 2017, Annual review of medicine.

[5]  S. Friend,et al.  Crowdsourcing biomedical research: leveraging communities as innovation engines , 2016, Nature Reviews Genetics.

[6]  G. Yancopoulos,et al.  Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.

[7]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[8]  S. Chimenti,et al.  Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial , 2015, The Lancet.

[9]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[10]  Nci Dream Community.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .

[11]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[12]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[13]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[14]  F. Villanova,et al.  Biomarkers in psoriasis and psoriatic arthritis , 2013, Annals of the rheumatic diseases.

[15]  Shahar Barbash,et al.  Statistically invalid classification of high throughput gene expression data , 2013, Scientific Reports.

[16]  Robert Tibshirani,et al.  Classification of patients from time-course gene expression. , 2013, Biostatistics.

[17]  R. Dellavalle,et al.  The role of systematic reviews and meta-analysis in dermatology. , 2012, The Journal of investigative dermatology.

[18]  A. Troxel,et al.  Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. , 2012, Archives of dermatology.

[19]  Vanessa B. Sequeira,et al.  The role of the vitamin D receptor and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3. , 2012, Molecular endocrinology.

[20]  A. Towse,et al.  The R&D Cost of a New Medicine , 2012 .

[21]  M. Suárez-Fariñas,et al.  Resolved psoriasis lesions retain expression of a subset of disease-related genes. , 2011, The Journal of investigative dermatology.

[22]  Xin Wang,et al.  Bioinformatics Applications Note Systems Biology Htsanalyzer: an R/bioconductor Package for Integrated Network Analysis of High-throughput Screens , 2022 .

[23]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[24]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[25]  Elizabeth J Horn,et al.  National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. , 2008, Journal of the American Academy of Dermatology.

[26]  S. Timmermans,et al.  The promises and pitfalls of evidence-based medicine. , 2005, Health affairs.

[27]  Ian H. Witten,et al.  Issues in Stacked Generalization , 2011, J. Artif. Intell. Res..

[28]  Peter Clark,et al.  Rule Induction with CN2: Some Recent Improvements , 1991, EWSL.